These findings laid the rationale for the use of low-dose IL-2 in SLE, which had been shown to be therapeutically effective in graft-versus-host disease (GHVD), type 1 diabetes, and vasculitis.[43] A chronological summary of the clinical trials using low-dose IL-2 is reported in Table 1. Here, IL2 is linked to graft versus host disease.